TT 10

Drug Profile

TT 10

Alternative Names: Autologous EBV specific Cytotoxic T Lymphocytes - Tessa Therapeutics; EB-VST - Tessa Therapeutics; EBV-CTL; Epstein-Barr virus specific autologous cytotoxic T-lymphocytes therapy - Tessa Therapeutics; Epstein-Barr virus specific T cells - Tessa Therapeutics; TT10; TT10-EB VST

Latest Information Update: 07 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Cancer Centre (Singapore)
  • Developer National Cancer Centre (Singapore); Tessa Therapeutics
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action Immunomodulators; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Nasopharyngeal cancer
  • Preclinical Gastric cancer

Most Recent Events

  • 05 Feb 2018 Efficacy and adverse events data from a phase II trial in Nasopharyngeal cancer released by Tessa Therapeutics
  • 30 Sep 2015 TT 10 receives Fast track status from the US FDA for EBV-positive Head and neck cancers, including Nasopharyngeal carcinoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top